Purchase this article with an account.
Tatsushi Kawaguchi, Yuko Iwasaki, Sayaka Kanda, Sunao Sugita, Manabu Mochizuki; Clinical Course of Patients with Behcet's Uveoretinitis that Discontinued Infliximab Therapy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6232.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate clinical course of patients with Behçet's uveoretinitis that discontinued infliximab (IFX) therapy.
Subjects were uveitis patients associated with Behçet’s disease that received IFX treatment at Tokyo Medical and Dental University Hospital between 2000 and 2011. Medical records of patients who discontinued IFX were reviewed retrospectively. The patients followed less than 12 months before and after IFX treatment were excluded. Frequency and severity of acute uveitis attacks, and visual prognosis were evaluated.
Of forty patients included in this study, nine patients (22.5%) discontinued IFX due to adverse events. In these patients, frequency of acute uveitis attack (mean/month) was 0.56 before IFX, 0.22 during IFX, and 0.06 after cessation of IFX. The frequency of uveitis attacks was statistically higher before IFX compared to during IFX (p<0.01), and after cessation of IFX (p<0.01), while there was no statistical significance between during IFX and after cessation of IFX (p=0.12). The severity of uveitis attacks was tend to be higher in the periods before IFX compared to during IFX, or after cessation of IFX. The average of visual acuity was 0.25 before IFX, 0.30 during IFX, 0.37 at 12 months after cessation of IFX, and there was no statistical significance between them.
Clinical course of Behçet's uveoretinitis after cessation of IFX appears to be satisfactory with well-controlled ocular inflammation. These data suggest a possibility for secure, planned discontinuation of IFX therapy in Behçet's uveoretinitis.
This PDF is available to Subscribers Only